Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher ...

Danish vaccine specialist Bavarian Nordic (OMX: BAVA) is set to collect $160 million from the sale of a US priority review ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by ...

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today ...